NCT00074009View on ClinicalTrials.gov

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2005

Conditions
Gastric Cancer
Interventions
DRUG

bortezomib

Trial Locations (4)

10021

Memorial Sloan-Kettering Cancer Center, New York

11432

Queens Cancer Center of Queens Hospital, Jamaica

60637-1470

University of Chicago Cancer Research Center, Chicago

53792-3236

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00074009 - Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter